Newly Diagnosed Glioblastoma
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma: A Randomized Double-blind Multicenter Prospective Phase II Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Zhongping Chen, Doctor
- Phone Number: 13500002457
- Email: chenzhp@sysucc.org.cn
Study Contact Backup
- Name: Yuanyuan Chen, Doctor
- Phone Number: 13738103808
- Email: chenyy@zjcc.org.cn
Study Locations
-
-
Anhui
-
Bengbu, Anhui, China, 233004
- the First Affiliated Hospital of Bengbu Medical College
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100070
- Beijing Tiantan Hospital,Capital Medical University
-
Beijing, Beijing Municipality, China, 100142
- The Sixth Madical Center of PLA General Hospital
-
Beijing, Beijing Municipality, China, 100853
- The General Hospital of the People's Liberation Army (PLAGH)
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400000
- Chongqing University Cancer Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350014
- Fujian Provincial Cancer Hospital
-
-
Gansu
-
Lanzhou, Gansu, China, 730000
- The First Hospital of Lanzhou University
-
Lanzhou, Gansu, China, 730000
- Lanzhou University Second Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
Shenzhen, Guangdong, China, 518000
- Shenzhen People's Hospital
-
Zhuhai, Guangdong, China, 519000
- The Fifth Affiliated Hospital Sun Yat-Sen University
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Henan Cancer Hospital
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221000
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The First Affiliated Hospital of Nanchang University
-
Nanchang, Jiangxi, China, 330029
- Jiangxi Cancer Hospital
-
-
Lanzhou Province
-
Gansu, Lanzhou Province, China, 730000
- GanSu Provincial Hospital
-
-
Liaoning
-
Shenyang, Liaoning, China, 110042
- Liaoning Cancer Hospital & Institute
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200433
- Fudan University shabghai cancer center
-
-
Shanxi
-
Xian, Shanxi, China, 710000
- The Second Affiliated Hospital of PLA Air Force Medical University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital,Sichuan University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300052
- Tianjin Medical University General Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Zhejiang Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Understood and Signed an informed consent form., with good compliance
- Age: 18-75 years old;.Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;Life expectancy of at least 3 months.
- Glioblastoma confirmed by histology ;
- Random time is 4-6 weeks from the last operation , and the investigator judges that the surgical wound has healed well;
- Within 5 days before administration, the dosage of corticosteroids was stable or gradually decreased;
- Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study ;Not Pregnant or breastfeeding women,Pregnancy before pregnancy screening, the women who blood / urine results were positivetherapy.
Exclusion Criteria:
- Have previously received systemic radiotherapy and chemotherapy for GBM;
- IDH1/2 mutations are present
- Contraindicated for MRI examination
- The tumor only occurs in the brain stem
- Radiologically obvious diffuse meningeal dissemination
- Imaging shows that the tumor has invaded the periphery of important blood vessels or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal hemorrhage, cerebrovascular malformations or other bleeding tendency during the subsequent study period;
- Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident , deep vein thrombosis and pulmonary embolism;
- Other malignant tumors have occurred or are currently present at the same time within 3 years.
- There are many factors that affect oral medications ;
- Received anti-tumor Chinese patent medicine which were approved by NMPA Within 2 weeks before the start of the study.
- A clear history of neurological or psychiatric diseases, moderate or higher epilepsy , moderate or higher aphasia or dementia
- Participated in other anti-tumor drug clinical trials within 4 weeks before grouping;
- Other conditions which are not fit for this study assessed by investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental group
Experimental: Radiation therapy, Temozolomide and anlotinib Patients will receive standard radiation therapy plus temozolomide (Stupp regimen).
Anlotinib hydrochloride will be given with a daily dose of 10 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
|
Drug: Anlotinib Hydrochloride Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0
Gy given 5 days a week for a total of 54-60 Gy.
Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy.
Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
|
|
Placebo Comparator: control group
Experimental: Radiation therapy, Temozolomide and Placebo Patients will receive standard radiation therapy plus temozolomide (Stupp regimen).
Placebo will be given with a daily dose of 0 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
|
Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0
Gy given 5 days a week for a total of 54-60 Gy.
Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy.
Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression Free Survival (PFS) assessed by IRC
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
PFS was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The progression free survival (PFS)
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
PFS was defined as the time from the date of study enrollment to the date of the first of the following events: objective disease progression or death due to any cause.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
|
Overall survival (OS)
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
OS was defined as the time from the date of study enrollment to the date of death due to any cause.
Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zhongping Chen, Doctor, Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Therapeutics
- Azoles
- Dacarbazine
- Triazenes
- Imidazoles
- Temozolomide
- Radiotherapy
Other Study ID Numbers
Other Study ID Numbers
- ALTN-Ⅱ-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.